PTO/SB/26 (01-08)
Approved for use through 05/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT		Docket Number (Optional)	
		CPC-10003/22	
In re Application of: Scott Wepfer			
Application No.: 10/645,951-Conf. #8257			
Filed: August 22, 2003			
For: TOPICAL ANESTHETIC FORMULATION			
The owner*, Scott Wepfer , of 100 percent interest in the Instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of prior patent No. 7,273,887 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior			
application that would extend to the expiration date patent, "as the term of said prior patent is present later: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction is statutorily disclaimed in whole or terminally dischas all claims canceled by a reexamination certification is reissued; or is in any manner terminated prior to the expiration	ly shortened by any terminal disclaimer," in n; daimed under 37 CFR 1.321; date;	i the event that said prior patent	
Check either box 1 or 2 below, if appropriate.			
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.			
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.			
2. X The undersigned is an attorney or agent of	of record. Reg. No. 39,204	<u></u>	
/Avery N. G	oldstein, Ph.D./	May 27, 2008	
	nature	Date	
Avery N. Goldstein, Ph.D.			
	Typed or printed name		
		(248) 647-6000 Telephone Number	
X Terminal disclaimer fee under 37 CFR 1,20(c	f) is included.	relephone Maribes	
	form may become public. Credit card in de credit card information and authoriza		
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).			
Form PTO/SB/96 may be used for making this certification. See MPEP § 324.			

PTO/SB/25 (01-08)
Approved for use through 05/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING	Docket Number (Optional)		
REJECTION OVER A PENDING "REFERENCE" APPLICATION	CPC-10003/22		
In re Application of: Scott Wepfer			
Application No.: 10/645,951-Conf. #8257			
Filed: August 22, 2003			
For: TOPICAL ANESTHETIC FORMULATION			
The owner*, Scott Wepfer , of 100			
percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any			
patent granted on pending reference Application Number 11/835.500 filed on 8/8/2007			
as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner			
nereby agrees that any patent so granted on the instant application shall be enforceable only for and duting such period that it			
and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.			
-			
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said			
reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that: any such patent: granted			
on the pending reference application; expires for failure to pay a maintenance fee, is held upenforceable, is found invalid by a			
court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1,321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term			
as shortened by any terminal disclaimer filed prior to its grant.			
Check either box 1 or 2 below, if appropriate.			
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.			
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on			
Information and belief are believed to be true; and further that these statements were made with	the knowledge that willful false		
statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.			
2. X The undersigned is an attorney or agent of record. Reg. No.			
2. X The undersigned is an attorney or agent of record. Reg. No. 39,204			
/Avery N. Goldstein, Ph.D./	May 27, 2008		
Signature	Date		
Avery N. Goldstein, Ph.D.			
Typed or printed name			
	(248) 647-6000 elephone Number		
	erabitotie Montoer		
X Terminal disclaimer fee under 37 CFR 1.20(d) is included.			
WARNING: Information on this form may become public. Credit card information should not			
be included on this form. Provide credit card informationand authorization on PTO-2038.			
"Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.			
Tomas Toxobias may be page for making this attractions. See MFEF 9 324.			